Reversible glycosidic switch for secure delivery of molecular nanocargos

Burnouf, Pierre-Alain; Leu, Yu Lin; Su, Yu-Cheng; Wu, Kenneth C.; Lin, Wei Chi; Roffler, Steve R.

doi:10.1038/s41467-018-04225-5

Cited by 18 publications

(14 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prodrugs, which can be converted into pharmacological drugs at desired sites, are widely used in cancer chemotherapy . To date, overexpressed enzymes (e.g., matrix metalloproteinase, glutathione S‐transferase, and β‐glucuronidase) within tumor tissues that can direct the conversion of the prodrugs have been broadly reported owing to their higher catalytic activity. However, certain restrictive factors for this strategy remained, such as limited number of enzymes that can be used and poor adjustability of endogenous enzymes .…”

Section: Methodsmentioning

confidence: 99%

Activation of Prodrugs by NIR‐Triggered Release of Exogenous Enzymes for Locoregional Chemo‐photothermal Therapy

et al. 2019

View full text Add to dashboard Cite

Enzymes have been used to direct the conversion of prodrugs in cancer therapy. However, non‐specific distribution of endogenous enzymes seriously hinders their bioapplications. Herein, we developed a near‐infrared‐triggered locoregional chemo‐photothermal therapy based on the exogenous enzyme delivery and remolded tumor mivroenvironment. The catalytic efficiency of enzymes was enhanced by the hyperthermia, and the therapeutic efficacy of photothermal therapy (PTT) was improved owing to the inhibition of heat shock protein 90 by chemotherapeutics. The locoregional chemo‐phototherapy achieved a one‐time successful cure in 4T1 tumor‐bearing mice model. Thus, a mutually reinforcing feedback loop between PTT and chemotherapy can be initiated by the irradiation, which holds a promising future in cancer therapy.

show abstract

Section: Methodsmentioning

confidence: 99%

Activation of Prodrugs by NIR‐Triggered Release of Exogenous Enzymes for Locoregional Chemo‐photothermal Therapy

et al. 2019

View full text Add to dashboard Cite

show abstract

“…When activated, the clue-responsive trigger releases the original drug molecule. Liposomes with “On” and “Off” responsive glucosidase (triggered by reaction with lysosomal beta-glucuronidase) switches [ 245 ] and thermosensitive leucine zipper lipopeptide anchored in the liposomal bilayer [ 246 ] have been constructed. Using the insertion of a copolymer consisting of an azobenzene group linked with PDPA, reversible get-in and get-out blocks in the liposome bilayer were obtained that could ultimately realize complete drug release under UV-irradiation and pH stimuli [ 247 ].…”

Section: Dual-sensitive Liposomesmentioning

confidence: 99%

Updates on Responsive Drug Delivery Based on Liposome Vehicles for Cancer Treatment

2022

View full text Add to dashboard Cite

Liposomes are well-known nanoparticles with a non-toxic nature and the ability to incorporate both hydrophilic and hydrophobic drugs simultaneously. As modern drug delivery formulations are produced by emerging technologies, numerous advantages of liposomal drug delivery systems over conventional liposomes or free drug treatment of cancer have been reported. Recently, liposome nanocarriers have exhibited high drug loading capacity, drug protection, improved bioavailability, enhanced intercellular delivery, and better therapeutic effect because of resounding success in targeting delivery. The site targeting of smart responsive liposomes, achieved through changes in their physicochemical and morphological properties, allows for the controlled release of active compounds under certain endogenous or exogenous stimuli. In that way, the multifunctional and stimuli-responsive nanocarriers for the drug delivery of cancer therapeutics enhance the efficacy of treatment prevention and fighting over metastases, while limiting the systemic side effects on healthy tissues and organs. Since liposomes constitute promising nanocarriers for site-targeted and controlled anticancer drug release, this review focuses on the recent progress of smart liposome achievements for anticancer drug delivery applications.

show abstract

“…Nowadays, edible and multifunctional nanocarriers such as proteins, lipids and polysaccharides have gained much attention in drug delivery engineering owing to their eco‐friendly, safety and biocompatibility characteristics 1‐4 . In addition to those polymeric molecules, for delivery of hydrophobic molecules in aqueous media, micellar solubilization driven by small molecular surfactants has been considered as a promising technology due to the simplicity and low cost 5,6 …”

Section: Introductionmentioning

confidence: 99%

A comparative study on physicochemical and micellar solubilization performance between monoglucosyl rebaudioside A and rebaudioside A

et al. 2021

View full text Add to dashboard Cite

BACKGROUND Rebaudioside A (RA) and its monoglucosyl derivative, as like rebaudioside D (RD) are the most popular stevia glycosides but possess poor solubility in water, which limited their application as edible surfactants, the applications as in micellar solubilization and drug delivery. Meanwhile, effect of the monoglucosyl attached to RA moiety remains unclear. RESULTS Monoglucosyl rebaudioside A (RAG1) was synthesized via hydrolyzing the transglycosylation product of RA with 95% of RA converted. RAG1 content in raw reaction mixture was as high as 69.5% of total glycosides, and harvested with a content of 88.2% by simple filtration. The RAG1 exhibited an aqueous solubility of 87 folds of RA or 391 folds of RD at 25 °C. The surface activity of RAG1 solution was higher than RA and invincible to RD. The RAG1 micelles promoted aqueous solubility of idebenone (IDE) up to 500 folds higher at 25 °C. The cumulative release rate of IDE encapsulated in RAG1 micelles was 777.5% or 456.7% higher of that of free IDE in simulated gastric/intestinal fluids in 14 h, respectively. The RAG1‐IDE remained the same in 98 days at 25 °C. CONCLUSION The α‐linked glucosyl to RA induced higher hydrophilicity and surface activity than that resulted by β‐linked glucosyl, making RAG1 not only dramatically raise the aqueous solubility of RA, but also endow IDE folds higher in bioaccessibility, yet making the capsule stable at storage. The results would provide a new edible delivery nanocarrier for encapsulation of hydrophobic bioactive components. © 2021 Society of Chemical Industry.

show abstract

Reversible glycosidic switch for secure delivery of molecular nanocargos

Cited by 18 publications

References 58 publications

Activation of Prodrugs by NIR‐Triggered Release of Exogenous Enzymes for Locoregional Chemo‐photothermal Therapy

Activation of Prodrugs by NIR‐Triggered Release of Exogenous Enzymes for Locoregional Chemo‐photothermal Therapy

Updates on Responsive Drug Delivery Based on Liposome Vehicles for Cancer Treatment

A comparative study on physicochemical and micellar solubilization performance between monoglucosyl rebaudioside A and rebaudioside A

Contact Info

Product

Resources

About